New advances in the biology and treatment of myeloma bone disease.
about
Newly diagnosed multiple myeloma.Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass spectrometry.Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma.Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?
P2860
New advances in the biology and treatment of myeloma bone disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
New advances in the biology and treatment of myeloma bone disease.
@ast
New advances in the biology and treatment of myeloma bone disease.
@en
New advances in the biology and treatment of myeloma bone disease.
@nl
type
label
New advances in the biology and treatment of myeloma bone disease.
@ast
New advances in the biology and treatment of myeloma bone disease.
@en
New advances in the biology and treatment of myeloma bone disease.
@nl
prefLabel
New advances in the biology and treatment of myeloma bone disease.
@ast
New advances in the biology and treatment of myeloma bone disease.
@en
New advances in the biology and treatment of myeloma bone disease.
@nl
P1476
New advances in the biology and treatment of myeloma bone disease.
@en
P2093
Berenson JR
P356
10.1016/S0037-1963(01)90090-3
P433
P577
2001-04-01T00:00:00Z